Klinique Competitors

KLINIQ Stock

31.50 0.75 2.44%

Klinique Med competes with Com7 PCL, Gunkul Engineering, Sappe Public, and AP Public; as well as few others. The company operates under Consumer Cyclical sector and is part of Personal Services industry. Analyzing Klinique Med competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Klinique Med to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Klinique Med Correlation with its peers.

You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of Klinique Med competition on your existing holdings.

Specify up to 10 symbols:

Hype

Prediction

Low	Estimated	High
29.59	31.50	33.41

Details

Intrinsic

Valuation

Low	Real	High
25.39	27.30	34.65

Details

Klinique Med Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Klinique Med and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Klinique and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Klinique Med does not affect the price movement of the other competitor.

	COM7	GUNKUL	ITC	SAPPE	AP
COM7		-0.34	0.27	0.13	-0.24	COM7
GUNKUL	-0.34		0.46	-0.62	0.95	GUNKUL
ITC	0.27	0.46		-0.57	0.5	ITC
SAPPE	0.13	-0.62	-0.57		-0.56	SAPPE
AP	-0.24	0.95	0.5	-0.56		AP
	COM7	GUNKUL	ITC	SAPPE	AP

Click cells to compare fundamentals

Check Volatility

Backtest Portfolio

High positive correlations

AP	+ 0.95	GUNKUL
AP	+ 0.5	ITC
ITC	+ 0.46	GUNKUL
ITC	+ 0.27	COM7
SAPPE	+ 0.13	COM7

High negative correlations

SAPPE	- 0.62	GUNKUL
SAPPE	- 0.57	ITC
AP	- 0.56	SAPPE
GUNKUL	- 0.34	COM7
AP	- 0.24	COM7

Risk-Adjusted Indicators

There is a big difference between Klinique Stock performing well and Klinique Med Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Klinique Med's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.

	Mean Deviation	Jensen Alpha	Sortino Ratio	Treynor Ratio	Semi Deviation	Expected Shortfall	Potential Upside	Value @Risk	Maximum Drawdown
COM7	1.72	0.19	0.04	1.85	1.90	(2.17)	3.92	(3.28)	12.15
GUNKUL	1.93	0.11	(0.04)	(0.03)	2.13	(2.49)	4.00	(4.17)	11.36
ITC	1.62	0.07	(0.03)	(0.48)	1.88	(1.80)	4.00	(2.97)	11.44
SAPPE	1.69	0.16	0.00	(0.32)	1.66	(2.06)	3.83	(2.76)	14.17
AP	1.31	0.02	(0.05)	0.35	1.39	(1.93)	3.00	(2.48)	10.37

Unable to evaluate fundamental data of [COM7.BK, GUNKUL.BK, ITC.BK, SAPPE.BK, AP.BK] at this time. Please try again later

All Fundamental Data

Klinique Med Competitive Analysis

The better you understand Klinique Med competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Klinique Med's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Klinique Med's competition over several years is one of the best ways to analyze its investment potential.

Better Than Average

Worse Than Peers

View Performance Chart

	KLINIQ	COM7	GUNKUL	ITC	SAPPE	AP
	2.44 31.50 Klinique	1.85 26.50 Com7	0.86 2.30 Gunkul	1.45 20.40 ITC	1.61 76.50 Sappe	1.16 8.70 AP Public
Market Volatility (90 Days Market Risk)	Very steady	Very steady	Unstable	Not too volatile	Very steady	Somewhat reliable
Market Performance (90 Days Performance)	Very Weak	Modest	Very Weak	Weak	Modest	Weak
Odds of Financial Distress (Probability Of Bankruptcy)	Low	Low	Low	Unknown	Low	Low
Current Valuation (Equity Enterprise Value)	Over Valued	Fairly Valued	Over Valued	Over Valued	Over Valued	Over Valued
Buy or Sell Advice (Average Analysts Consensus)	Not Available	Not Available	Not Available	Not Available	Not Available	Not Available
Trade Advice (90 Days Macroaxis Advice)	Strong Sell	Cautious Hold	Strong Sell	Strong Sell	Strong Sell	Strong Sell
Current Ratio	N/A	1.35 X	0.97 X		3.17 X	3.28 X
Net Asset	N/A	15.97 B	42.49 B		3.85 B	60.41 B
Profit Margin	0.13 %	0.05 %	0.47 %		0.12 %	0.15 %
EBITDA	288.81 M	4.02 B	4.92 B		716.61 M	5.9 B
Operating Margin	0.17 %	0.06 %	0.33 %		0.16 %	0.15 %
Current Valuation	9.44 B	84.27 B	61.4 B		10.49 B	52.39 B
Price To Book	39.18 X	12.22 X	3.31 X		4.01 X	0.95 X
Retained Earnings	N/A	646 M	2.49 B		547 M	N/A
Current Asset	N/A	2.78 B	6.95 B		1.04 B	N/A
Five Year Return	N/A	1.75 %	2.15 %		3.08 %	4.18 %
Beta	N/A	1.09	0.53		0.44	1.04
Number Of Employees	2	23	49		21	39
Shares Outstanding	220 M	2.38 B	8.88 B		308.29 M	3.15 B
Cash Flow From Operations	N/A	559.81 M	5.01 B		693.39 M	2.03 B
Annual Yield	N/A	0.03 %	0.03 %		0.02 %	0.04 %
Total Debt	N/A	2.88 B	18.63 B		77.09 M	14.72 B
Return On Equity	0.95	0.56	0.24		0.18	0.17
Z Score	N/A	18.0	1.2		N/A	1.2
Return On Asset	0.12	0.15	0.0387		0.11	0.0586
Book Value Per Share	0.95 X	2.66 X	1.65 X		10.09 X	11.31 X
Current Liabilities	N/A	1.95 B	6.28 B		489 M	N/A
Total Asset	N/A	15.97 B	42.49 B		3.85 B	60.41 B
Target Price	44.5	40.39	5.7		56.56	13.82
Last Dividend Paid	0.43	0.5	0.18		1.1	0.5
Debt To Equity	N/A	0.65 %	2.04 %		0.03 %	103.70 %
Shares Owned By Institutions	N/A	6.50 %	2.74 %		2.81 %	12.77 %
Market Capitalization	7.81 B	72.74 B	37.48 B		15.41 B	38.38 B
Price To Earning	N/A	49.15 X	13.60 X		19.79 X	6.76 X
Price To Earnings To Growth	N/A	N/A	0.45 X		N/A	1.71 X
Price To Sales	5.73 X	1.24 X	6.43 X		2.61 X	0.94 X
Net Income	N/A	2.63 B	2.23 B		410.81 M	4.54 B
Earnings Per Share	1.09 X	1.26 X	0.37 X		1.80 X	1.81 X
Shares Owned By Insiders	73.66 %	57.94 %	56.79 %		69.02 %	30.19 %
Revenue	1.49 B	51.13 B	8.35 B		3.44 B	31.79 B
Working Capital	N/A	831 M	668 M		555 M	N/A
Cash And Equivalents	N/A	1.61 B	3.27 B		1.43 B	1.51 B
Cash Per Share	N/A	1.34 X	0.37 X		4.66 X	0.48 X
Gross Profit	558.77 M	6.87 B	2.33 B		1.62 B	10.48 B
Day Typical Price	31.42	26.58	2.3	20.43	77.17	8.65
Accumulation Distribution	0.0391	179465.0	70539.67	0.0337	0.0255	119937.0
Market Facilitation Index	1.25	N/A	N/A	0.7	2.0	N/A
Daily Balance Of Power	0.6	(0.67)	(0.50)	(0.43)	(0.62)	0.6667
Period Momentum Indicator	0.75	(0.50)	(0.02)	(0.30)	(1.25)	0.1
Rate Of Daily Change	1.02	0.98	0.99	0.99	0.98	1.01
Day Median Price	31.38	26.63	2.3	20.45	77.5	8.63
Price Action Indicator	0.5	(0.37)	(0.01)	(0.20)	(1.62)	0.12
Coefficient Of Variation	(1,053)	1092.61	8211.43	3217.04	1815.86	4268.47
Mean Deviation	1.39	1.72	1.93	1.62	1.69	1.31
Jensen Alpha	(0.15)	0.1884	0.1057	0.0738	0.1617	0.0224
Total Risk Alpha	(0.47)	(0.15)	(0.35)	(0.28)	(0.23)	(0.25)
Sortino Ratio	N/A	0.0373	(0.04)	(0.03)	0.0018	(0.05)
Downside Variance	N/A	5.28	6.34	4.91	3.23	2.95
Standard Deviation	1.87	2.31	2.49	2.24	2.34	1.85
Kurtosis	1.36	1.02	0.1243	2.04	6.42	2.26
Potential Upside	2.54	3.92	4.0	4.0	3.83	3.0
Treynor Ratio	0.6296	1.85	(0.03)	(0.48)	(0.32)	0.3521
Maximum Drawdown	9.7	12.15	11.36	11.44	14.17	10.37
Variance	3.51	5.31	6.18	5.01	5.45	3.42
Market Risk Adjusted Performance	0.6396	1.86	(0.02)	(0.47)	(0.31)	0.3621
Risk Adjusted Performance	(0.07)	0.0768	0.0163	0.0304	0.0489	0.0238
Skewness	(0.55)	0.2824	0.3685	0.9666	1.8	0.941
Semi Deviation	N/A	1.9	2.13	1.88	1.66	1.39
Information Ratio	(0.16)	0.0371	(0.04)	(0.02)	0.0014	(0.04)
Value At Risk	(4.10)	(3.28)	(4.17)	(2.97)	(2.76)	(2.48)
Expected Short fall	N/A	(2.17)	(2.49)	(1.80)	(2.06)	(1.93)
Downside Deviation	N/A	2.3	2.52	2.22	1.8	1.72
Semi Variance	N/A	3.6	4.52	3.54	2.74	1.92

Klinique Med Competition Performance Charts

Five steps to successful analysis of Klinique Med Competition

Klinique Med's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Klinique Med in relation to its competition. Klinique Med's competition analysis typically involves several steps, including:

Identifying the key players in the market: This involves identifying the major competitors of Klinique Med in the market, both direct and indirect, as well as new entrants and disruptive technologies.
Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Klinique Med's competitive landscape.
Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Klinique Med, and developing a strategy to address them.
Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.

Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your Klinique Med position

In addition to having Klinique Med in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Computers Thematic Idea Now

Computers

Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Computers theme has 61 constituents at this time.

You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Computers Theme or any other thematic opportunities.

View All Next

Launch

Other Information on Investing in Klinique Stock

Klinique Med financial ratios help investors to determine whether Klinique Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Klinique with respect to the benefits of owning Klinique Med security.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC